Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism.

Konstorum A, Lynch ML, Torti SV, Torti FM, Laubenbacher RC.

OMICS. 2018 Jul;22(7):502-513. doi: 10.1089/omi.2018.0060.

PMID:
30004845
2.

Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.

Blanchette-Farra N, Kita D, Konstorum A, Tesfay L, Lemler D, Hegde P, Claffey KP, Torti FM, Torti SV.

Oncogene. 2018 Apr 26. doi: 10.1038/s41388-018-0243-y. [Epub ahead of print]

PMID:
29695834
3.

Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth.

Deng Z, Manz DH, Torti SV, Torti FM.

Oncotarget. 2017 Jul 17;8(47):82231-82243. doi: 10.18632/oncotarget.19288. eCollection 2017 Oct 10.

4.

Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.

Deng Z, Manz DH, Torti SV, Torti FM.

Antioxid Redox Signal. 2017 Dec 11. doi: 10.1089/ars.2017.7023. [Epub ahead of print]

PMID:
29061069
5.

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease.

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD.

Cell. 2017 Oct 5;171(2):273-285. doi: 10.1016/j.cell.2017.09.021. Review.

PMID:
28985560
6.

Iron addiction: a novel therapeutic target in ovarian cancer.

Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller LD, Dyment N, Torti FM, Torti SV.

Oncogene. 2017 Jul 20;36(29):4089-4099. doi: 10.1038/onc.2017.11. Epub 2017 Mar 20.

7.

DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.

Lemler DJ, Lynch ML, Tesfay L, Deng Z, Paul BT, Wang X, Hegde P, Manz DH, Torti SV, Torti FM.

Breast Cancer Res. 2017 Mar 7;19(1):25. doi: 10.1186/s13058-017-0814-9.

8.

Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts.

Torti SV, Lemler E, Mueller BK, Popp A, Torti FM.

Clin Exp Pharmacol. 2016 Nov;6(6). pii: 223. doi: 10.4172/2161-1459.1000223. Epub 2016 Nov 17.

9.

Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective.

Chifman J, Arat S, Deng Z, Lemler E, Pino JC, Harris LA, Kochen MA, Lopez CF, Akman SA, Torti FM, Torti SV, Laubenbacher R.

PLoS Comput Biol. 2017 Feb 6;13(2):e1005352. doi: 10.1371/journal.pcbi.1005352. eCollection 2017 Feb.

10.

Mitochondria and Iron: current questions.

Paul BT, Manz DH, Torti FM, Torti SV.

Expert Rev Hematol. 2017 Jan;10(1):65-79. doi: 10.1080/17474086.2016.1268047. Epub 2016 Dec 12. Review.

11.

Incidental cervical metastases from thyroid carcinoma during neck dissection.

Périé S, Torti F, Lefevre M, Chabbert-Buffet N, Jafari A, Lacau St Guily J.

Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Dec;133(6):383-386. doi: 10.1016/j.anorl.2016.07.002. Epub 2016 Jul 26.

12.

Iron and cancer: recent insights.

Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV.

Ann N Y Acad Sci. 2016 Mar;1368(1):149-61. doi: 10.1111/nyas.13008. Epub 2016 Feb 18. Review.

13.

Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Blanchette NL, Manz DH, Torti FM, Torti SV.

Expert Rev Hematol. 2016;9(2):169-86. doi: 10.1586/17474086.2016.1124757. Epub 2015 Dec 15. Review.

14.

Cytoprotective Effect of Ferritin H in Renal Ischemia Reperfusion Injury.

Hatcher HC, Tesfay L, Torti SV, Torti FM.

PLoS One. 2015 Sep 17;10(9):e0138505. doi: 10.1371/journal.pone.0138505. eCollection 2015.

15.

Hepcidin regulation in prostate and its disruption in prostate cancer.

Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.

Cancer Res. 2015 Jun 1;75(11):2254-63. doi: 10.1158/0008-5472.CAN-14-2465. Epub 2015 Apr 9.

16.

Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.

Chakradeo S, Sharma K, Alhaddad A, Bakhshwin D, Le N, Harada H, Nakajima W, Yeudall WA, Torti SV, Torti FM, Gewirtz DA.

Mol Pharmacol. 2015 May;87(5):803-14. doi: 10.1124/mol.114.095273. Epub 2015 Feb 9.

17.

A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.

Sharma K, Goehe RW, Di X, Hicks MA 2nd, Torti SV, Torti FM, Harada H, Gewirtz DA.

Autophagy. 2014;10(12):2346-61. doi: 10.4161/15548627.2014.993283.

18.

Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals.

Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, Piechotta M, Levanon EY, Landthaler M, Dieterich C, Rajewsky N.

Cell Rep. 2015 Jan 13;10(2):170-7. doi: 10.1016/j.celrep.2014.12.019. Epub 2014 Dec 31.

19.

Global characterization of the oocyte-to-embryo transition in Caenorhabditis elegans uncovers a novel mRNA clearance mechanism.

Stoeckius M, Grün D, Kirchner M, Ayoub S, Torti F, Piano F, Herzog M, Selbach M, Rajewsky N.

EMBO J. 2014 Aug 18;33(16):1751-66. doi: 10.15252/embj.201488769. Epub 2014 Jun 23.

20.

Epidemiological associations between iron and cardiovascular disease and diabetes.

Basuli D, Stevens RG, Torti FM, Torti SV.

Front Pharmacol. 2014 May 20;5:117. doi: 10.3389/fphar.2014.00117. eCollection 2014. Review.

21.

The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated.

Huhn AJ, Parsonage D, Horita DA, Torti FM, Torti SV, Hollis T.

Protein Sci. 2014 Aug;23(8):1013-22. doi: 10.1002/pro.2486. Epub 2014 May 22.

22.

IRP2 regulates breast tumor growth.

Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV.

Cancer Res. 2014 Jan 15;74(2):497-507. doi: 10.1158/0008-5472.CAN-13-1224. Epub 2013 Nov 27.

23.

The new University of Connecticut Health Center.

Torti FM.

Conn Med. 2013 Aug;77(7):431-2. No abstract available.

PMID:
24195183
24.

Cellular iron metabolism in prognosis and therapy of breast cancer.

Torti SV, Torti FM.

Crit Rev Oncog. 2013;18(5):435-48. Review.

25.

Application of circuit simulation method for differential modeling of TIM-2 iron uptake and metabolism in mouse kidney cells.

Xie Z, Harrison SH, Torti SV, Torti FM, Han J.

Front Physiol. 2013 Jun 7;4:136. doi: 10.3389/fphys.2013.00136. eCollection 2013.

26.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.

JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85. doi: 10.1016/j.jcmg.2012.11.017. Epub 2013 May 1.

27.

Ferritin H is a novel marker of early erythroid precursors and macrophages.

Wang W, Grier DD, Woo J, Ward M, Sui G, Torti SV, Torti FM, Beaty MW.

Histopathology. 2013 May;62(6):931-40. doi: 10.1111/his.12101.

PMID:
23611361
28.

Iron and cancer: more ore to be mined.

Torti SV, Torti FM.

Nat Rev Cancer. 2013 May;13(5):342-55. doi: 10.1038/nrc3495. Epub 2013 Apr 18. Review.

29.

Circular RNAs are a large class of animal RNAs with regulatory potency.

Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N.

Nature. 2013 Mar 21;495(7441):333-8. doi: 10.1038/nature11928. Epub 2013 Feb 27.

PMID:
23446348
30.

Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness.

Eckman DM, Stacey RB, Rowe R, D'Agostino R Jr, Kock ND, Sane DC, Torti FM, Yeboah J, Workman S, Lane KS, Hundley WG.

PLoS One. 2013;8(2):e57554. doi: 10.1371/journal.pone.0057554. Epub 2013 Feb 21.

31.

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP.

Cancer Discov. 2013 Apr;3(4):444-57. doi: 10.1158/2159-8290.CD-12-0388. Epub 2013 Jan 28.

32.

Heat localization for targeted tumor treatment with nanoscale near-infrared radiation absorbers.

Xie B, Singh R, Torti FM, Keblinski P, Torti S.

Phys Med Biol. 2012 Sep 21;57(18):5765-75. doi: 10.1088/0031-9155/57/18/5765. Epub 2012 Sep 5.

33.

Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells.

Tesfay L, Huhn AJ, Hatcher H, Torti FM, Torti SV.

PLoS One. 2012;7(7):e40030. doi: 10.1371/journal.pone.0040030. Epub 2012 Jul 2.

34.

Targeting Cancer Stem Cells with Nanoparticle-Enabled Therapies.

Burke AR, Singh RN, Carroll DL, Torti FM, Torti SV.

J Mol Biomark Diagn. 2012 Jul 2;Suppl 8. doi: 10.4172/2155-9929.S8-003.

35.

Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

36.

Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE.

Prostate. 2013 Jan;73(1):71-82. doi: 10.1002/pros.22542. Epub 2012 May 29.

37.

Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.

Krishnan B, Torti FM, Gallagher PE, Tallant EA.

Prostate. 2013 Jan;73(1):60-70. doi: 10.1002/pros.22540. Epub 2012 May 29.

PMID:
22644934
38.

The core control system of intracellular iron homeostasis: a mathematical model.

Chifman J, Kniss A, Neupane P, Williams I, Leung B, Deng Z, Mendes P, Hower V, Torti FM, Akman SA, Torti SV, Laubenbacher R.

J Theor Biol. 2012 May 7;300:91-9. doi: 10.1016/j.jtbi.2012.01.024. Epub 2012 Jan 23.

39.

The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy.

Burke AR, Singh RN, Carroll DL, Wood JC, D'Agostino RB Jr, Ajayan PM, Torti FM, Torti SV.

Biomaterials. 2012 Apr;33(10):2961-70. doi: 10.1016/j.biomaterials.2011.12.052. Epub 2012 Jan 14.

40.

Bioinformatics tools for cancer metabolomics.

Blekherman G, Laubenbacher R, Cortes DF, Mendes P, Torti FM, Akman S, Torti SV, Shulaev V.

Metabolomics. 2011 Sep;7(3):329-343. Epub 2011 Jan 12.

41.

Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells.

Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, Torti SV.

PLoS One. 2011;6(8):e23800. doi: 10.1371/journal.pone.0023800. Epub 2011 Aug 19.

42.

An iron regulatory gene signature predicts outcome in breast cancer.

Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM.

Cancer Res. 2011 Nov 1;71(21):6728-37. doi: 10.1158/0008-5472.CAN-11-1870. Epub 2011 Aug 29.

43.

Determinants of the thrombogenic potential of multiwalled carbon nanotubes.

Burke AR, Singh RN, Carroll DL, Owen JD, Kock ND, D'Agostino R Jr, Torti FM, Torti SV.

Biomaterials. 2011 Sep;32(26):5970-8. doi: 10.1016/j.biomaterials.2011.04.059. Epub 2011 Jun 12.

44.

Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy.

Ding X, Singh R, Burke A, Hatcher H, Olson J, Kraft RA, Schmid M, Carroll D, Bourland JD, Akman S, Torti FM, Torti SV.

Nanomedicine (Lond). 2011 Oct;6(8):1341-52. doi: 10.2217/nnm.11.37. Epub 2011 Apr 20.

45.

Ironing out cancer.

Torti SV, Torti FM.

Cancer Res. 2011 Mar 1;71(5):1511-4. doi: 10.1158/0008-5472.CAN-10-3614. Review.

46.

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.

Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV.

Breast Cancer Res Treat. 2011 Oct;129(3):737-46. doi: 10.1007/s10549-010-1261-9. Epub 2010 Nov 27.

47.

Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.

Blish KR, Clausen KA, Hawkins GA, Garvin AJ, Willingham MC, Turner JC, Torti FM, Torti SV.

J Exp Clin Cancer Res. 2010 Nov 16;29:147. doi: 10.1186/1756-9966-29-147.

48.

Breastfeeding in breast cancer survivors: pattern, behaviour and effect on breast cancer outcome.

Azim HA Jr, Bellettini G, Liptrott SJ, Armeni ME, Dell'Acqua V, Torti F, Di Nubila B, Galimberti V, Peccatori F.

Breast. 2010 Dec;19(6):527-31. doi: 10.1016/j.breast.2010.05.018.

PMID:
21078487
49.

Ferroportin and iron regulation in breast cancer progression and prognosis.

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.

Sci Transl Med. 2010 Aug 4;2(43):43ra56. doi: 10.1126/scisignal.3001127. Erratum in: Sci Transl Med. 2010 Aug 25;2(46):46er1.

50.

Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Jordan J, Workman S, Hundley WG.

Circ Cardiovasc Imaging. 2010 Sep;3(5):550-8. doi: 10.1161/CIRCIMAGING.109.918540. Epub 2010 Jul 9.

Supplemental Content

Support Center